<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Liquid Biopsy &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/liquid-biopsy/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Tue, 20 Jan 2026 10:58:04 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>Liquid Biopsy &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Harnessing Non-Coding RNAs for Real-Time Cancer Monitoring</title>
		<link>https://bioengineer.org/harnessing-non-coding-rnas-for-real-time-cancer-monitoring/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Tue, 20 Jan 2026 10:57:41 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[cancer monitoring]]></category>
		<category><![CDATA[Liquid Biopsy]]></category>
		<category><![CDATA[Minimally invasive diagnostics]]></category>
		<category><![CDATA[Non-coding RNAs]]></category>
		<category><![CDATA[precision oncology]]></category>
		<category><![CDATA[Real-time cancer monitoring]]></category>
		<category><![CDATA[real-time diagnostics]]></category>
		<guid isPermaLink="false">https://bioengineer.org/harnessing-non-coding-rnas-for-real-time-cancer-monitoring/</guid>

					<description><![CDATA[Recent advancements in precision oncology have opened new avenues for cancer monitoring and management, particularly with the integration of non-coding RNAs (ncRNAs). A groundbreaking study led by an international team of researchers, including prominent scientists Chang, Papazyan, and Pons-Tostivint, delves into the significant roles that these molecular entities can play in real-time cancer tracking. By [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">318860</post-id>	</item>
		<item>
		<title>CTCs Reveal Prostate Cancer’s Lethality Insights</title>
		<link>https://bioengineer.org/ctcs-reveal-prostate-cancers-lethality-insights/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Fri, 16 Jan 2026 18:13:39 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[cancer metastasis]]></category>
		<category><![CDATA[Circulating tumor cells]]></category>
		<category><![CDATA[Liquid Biopsy]]></category>
		<category><![CDATA[Liquid biopsy technology]]></category>
		<category><![CDATA[Makalenin içeriği ve anahtar kelimeleri dikkate alınarak en uygun 5 etiket: **Circulating Tumor Cells]]></category>
		<category><![CDATA[Metastatic Disease Insights]]></category>
		<category><![CDATA[personalized oncology strategies]]></category>
		<category><![CDATA[Prostate Cancer Prognosis]]></category>
		<category><![CDATA[Treatment Resistance** **Kısa açıklama:** 1. **Circulating Tumor Cells (CTCs):** Makalenin temel odağı ve araştırma konusu. 2. **Prostate Cancer Prognosis:**]]></category>
		<guid isPermaLink="false">https://bioengineer.org/ctcs-reveal-prostate-cancers-lethality-insights/</guid>

					<description><![CDATA[Prostate cancer stands as one of the most complex malignancies, characterized by its widespread multifocality, significant intra- and inter-patient heterogeneity, and varied progression characteristics ranging from indolence to aggressive metastatic disease. Such variability presents formidable challenges in accurately predicting patient outcomes, necessitating robust approaches for precise risk stratification. This underscores the urgency to develop innovative [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">317555</post-id>	</item>
		<item>
		<title>Liquid Biopsy AI Enhances Lung Cancer Progression Predictions</title>
		<link>https://bioengineer.org/liquid-biopsy-ai-enhances-lung-cancer-progression-predictions/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Tue, 06 Jan 2026 07:03:58 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[Cancer progression prediction]]></category>
		<category><![CDATA[İşte bu içerik için uygun 5 etiket: **AI in oncology]]></category>
		<category><![CDATA[kanser araştırmalarında yapay zekanın (özellikle PRIME modelinin) kullanımıdır. 2. **Liquid biopsy:**]]></category>
		<category><![CDATA[Liquid Biopsy]]></category>
		<category><![CDATA[non-small cell lung cancer]]></category>
		<category><![CDATA[Personalized medicine** **Açıklama:** 1. **AI in oncology:** Makalenin ana konusu]]></category>
		<guid isPermaLink="false">https://bioengineer.org/liquid-biopsy-ai-enhances-lung-cancer-progression-predictions/</guid>

					<description><![CDATA[In a remarkable breakthrough in cancer research, an innovative artificial intelligence model named PRIME (Predictive Risk Indicator for Metastasis and Extension) has been developed to enhance the prediction of progression risks in patients suffering from non-small cell lung cancer (NSCLC). This pioneering research, conducted by a team led by Dr. Y. Wang, has shown promising [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">314046</post-id>	</item>
		<item>
		<title>Exosomal microRNAs: Advancing Prostate Cancer Biomarkers, Therapies</title>
		<link>https://bioengineer.org/exosomal-micrornas-advancing-prostate-cancer-biomarkers-therapies/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Mon, 24 Nov 2025 07:57:51 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[Exosomal microRNAs]]></category>
		<category><![CDATA[Liquid Biopsy]]></category>
		<category><![CDATA[miRNA therapeutics]]></category>
		<category><![CDATA[prostate cancer biomarkers]]></category>
		<category><![CDATA[targeted therapy]]></category>
		<guid isPermaLink="false">https://bioengineer.org/exosomal-micrornas-advancing-prostate-cancer-biomarkers-therapies/</guid>

					<description><![CDATA[In the evolving landscape of oncology, prostate cancer continues to pose significant clinical challenges, spurring a relentless pursuit of advanced diagnostic tools and innovative therapies. A groundbreaking study published in Medical Oncology heralds transformative progress by illuminating the critical role of exosomal microRNAs (miRNAs) as both biomarkers and therapeutic agents in prostate cancer management. This [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">300425</post-id>	</item>
		<item>
		<title>New Method Detects TROP2+ Tumor Cells</title>
		<link>https://bioengineer.org/new-method-detects-trop2-tumor-cells/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Fri, 21 Nov 2025 11:31:37 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[Breast cancer diagnostics]]></category>
		<category><![CDATA[Circulating tumor cells]]></category>
		<category><![CDATA[Liquid Biopsy]]></category>
		<category><![CDATA[Magnetic nanoparticles]]></category>
		<category><![CDATA[TROP2 expression]]></category>
		<guid isPermaLink="false">https://bioengineer.org/new-method-detects-trop2-tumor-cells/</guid>

					<description><![CDATA[In an innovative leap forward in the fight against breast cancer, researchers have unveiled a groundbreaking method for detecting TROP2-positive circulating tumor cells (CTCs), potentially transforming the landscape of cancer diagnostics and personalized treatment strategies. The study, recently published in the prestigious journal BMC Cancer, introduces a novel magnetic nanoparticle-based platform designed to capture and [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">299463</post-id>	</item>
		<item>
		<title>Breakthrough “Ultra-Mild” Sequencing Technique Overcomes Key Limitations in Cancer DNA Methylation Analysis</title>
		<link>https://bioengineer.org/breakthrough-ultra-mild-sequencing-technique-overcomes-key-limitations-in-cancer-dna-methylation-analysis/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Thu, 13 Nov 2025 02:54:25 +0000</pubDate>
				<category><![CDATA[Chemistry]]></category>
		<category><![CDATA[Based on the content]]></category>
		<category><![CDATA[cancer diagnostics]]></category>
		<category><![CDATA[DNA methylation analysis]]></category>
		<category><![CDATA[epigenetics** **Explanation of the tags:** 1. **UMBS-seq:** The specific name of the breakthrough technique]]></category>
		<category><![CDATA[here are 5 appropriate tags: **UMBS-seq]]></category>
		<category><![CDATA[Liquid Biopsy]]></category>
		<guid isPermaLink="false">https://bioengineer.org/breakthrough-ultra-mild-sequencing-technique-overcomes-key-limitations-in-cancer-dna-methylation-analysis/</guid>

					<description><![CDATA[In a breakthrough that promises to significantly advance the field of cancer diagnostics, researchers from The University of Chicago have unveiled a revolutionary approach to DNA methylation analysis, called Ultra-Mild Bisulfite Sequencing or UMBS-seq. This novel method overcomes the critical limitations of existing technologies, offering a combination of accuracy, gentleness, and efficiency that could redefine [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">295906</post-id>	</item>
		<item>
		<title>Could Liquid Biopsy Testing Enable Earlier Detection Across Multiple Cancer Types?</title>
		<link>https://bioengineer.org/could-liquid-biopsy-testing-enable-earlier-detection-across-multiple-cancer-types/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Mon, 10 Nov 2025 08:22:16 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[Cancer Screening Innovation]]></category>
		<category><![CDATA[Cancer Stage Shift]]></category>
		<category><![CDATA[early cancer diagnosis]]></category>
		<category><![CDATA[Liquid Biopsy]]></category>
		<category><![CDATA[Multi-Cancer Early Detection (MCED)]]></category>
		<guid isPermaLink="false">https://bioengineer.org/could-liquid-biopsy-testing-enable-earlier-detection-across-multiple-cancer-types/</guid>

					<description><![CDATA[Routine cancer screening protocols have traditionally been confined to a narrow subset of malignancies, focusing primarily on four cancer types with established early detection methodologies. However, emerging evidence from novel research heralds a transformative shift in oncological diagnostics through the adoption of liquid biopsy technologies capable of multi-cancer early detection (MCED). This innovative approach leverages [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">293907</post-id>	</item>
	</channel>
</rss>
